Executive Summary
Eli Lilly deployed $2.75 billion across two acquisitions in a single day, signaling aggressive preparation for future patent cliffs despite current obesity drug dominance. The company acquired Orna Therapeutics for $2.4 billion and invested $350 million in Invent Biologics, both targeting next-generation RNA-based therapeutics. Bloomberg Intelligence's Sam Fazeli noted this reflects Lilly's 'massive cash flow' generation requiring pipeline diversification before investors begin questioning paten...
Key Investment Opportunity
Pharmaceutical Pipeline Diversification Play
Lilly's aggressive M&A spending reflects proactive patent cliff preparation, potentially creating value before market recognizes execution risk
...and 1 more investment opportunities
This is a preview. Log in to see the full analysis including investment opportunities, risks, catalysts, and detailed insights.